financetom
Business
financetom
/
Business
/
Exclusive-ExxonMobil selling Malaysia oil and gas assets to Petronas, sources say
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Exclusive-ExxonMobil selling Malaysia oil and gas assets to Petronas, sources say
Jul 19, 2024 4:26 AM

By Yantoultra Ngui and Florence Tan

SINGAPORE (Reuters) - Exxon Mobil Corp ( XOM ) has agreed to sell its Malaysian oil and gas assets to state energy firm Petronas, exiting the country's upstream sector where it used to be a dominant producer, two sources with direct knowledge of the matter said.

The U.S. major, which last year marked its 130th year in Malaysia, has been trying to sell its ageing upstream assets in the country since 2020, Malaysian media have reported, part of a shift in its strategy to focus on oil production in the Americas.

Petronas has taken over operations of Exxon's assets, including the country's flagship Tapis oilfield in Terengganu which began production in 1978, three sources said.

Exxon's staff would be transferred to Petronas as part of the deal, one of the sources said.

Petronas and ExxonMobil ( XOM ) did not respond to requests for comment.

The terms of the deal were not immediately known.

In an article posted on its website dated Nov. 12, 2023, Exxon said it remained a significant energy producer in Malaysia, contributing about 40% and 50%, respectively, to Peninsular Malaysia's crude oil and natural gas production.

The company operates 35 oil and gas platforms in 12 fields offshore Terengganu, and has a working interest in another 10 platforms in five fields in the South China Sea.

The combined operations produce about 15% of Malaysia's crude oil and condensate of 600,000 barrels a day, and more than half of peninsular Malaysia's natural gas of more than 2 billion cubic feet per day.

Its last major investment in the country was in a $2.5 billion enhanced oil recovery project at the Tapis field, which started up in late 2014.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US retailers aim to cash in on Cyber Monday with steep online discounts
US retailers aim to cash in on Cyber Monday with steep online discounts
Dec 2, 2024
(Reuters) - After lackluster spending at U.S. stores on a deals-heavy Black Friday, retailers will be pulling out all the stops with steep promotions on their websites and apps to entice people to buy holiday gifts and other merchandise after the long Thanksgiving weekend. Retailers have been coaxing cautious U.S. shoppers on Cyber Monday with push notifications, emails and other...
High Tide Up 3% To Fresh 52 Week High Levels In US Premarket As Expands Membership Program Across U.S., European Union, UK
High Tide Up 3% To Fresh 52 Week High Levels In US Premarket As Expands Membership Program Across U.S., European Union, UK
Dec 2, 2024
08:38 AM EST, 12/02/2024 (MT Newswires) -- High Tide (Nasdaq and TSXV: HITI), the second largest cannabis retailer in the world by store count, was at last look up more than 3% at fresh 52 week high levels in US premarket trade on Monday -- having jumped 14% on the Nasdaq last Friday -- after saying it was expanding its...
Cytokinetics Says US FDA Accepts New Drug Application for Aficamten to Treat Obstructive Hypertrophic Cardiomyopathy
Cytokinetics Says US FDA Accepts New Drug Application for Aficamten to Treat Obstructive Hypertrophic Cardiomyopathy
Dec 2, 2024
08:36 AM EST, 12/02/2024 (MT Newswires) -- Cytokinetics ( CYTK ) said Monday it has received acceptance for its new drug application of cardiac myosin inhibitor aficamten from the US Food and Drug Administration to treat obstructive hypertrophic cardiomyopathy. The decision was based on Cytokinetics' ( CYTK ) pivotal phase 3 clinical study for 24 weeks of aficamten that demonstrated...
Senti Biosciences Says 2 Patients Achieve Remission in Phase 1 Blood Cancer Trial
Senti Biosciences Says 2 Patients Achieve Remission in Phase 1 Blood Cancer Trial
Dec 2, 2024
08:38 AM EST, 12/02/2024 (MT Newswires) -- Senti Biosciences ( SNTI ) said Monday that two of three acute myeloid leukemia patients treated with its Senti-202 investigational cell therapy for relapsed or refractory hematologic malignancies, or blood cancers, achieved complete remission in a phase 1 trial. Both patients, who were treated at the lowest dose level, showed no measurable residual...
Copyright 2023-2026 - www.financetom.com All Rights Reserved